MedDataX Logo

Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients

NCT ID: NCT01727583

Last Updated: 2013-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, the investigators aim to investigate the effect of various lipid types on GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in nutritional solutions. Moreover, this will allow us to assess whether existing clinical formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lipid 1

Meal intake

Group Type ACTIVE_COMPARATOR

meal intake

Intervention Type DIETARY_SUPPLEMENT

Intake of meals characterized by lipid composition

Lipid-free

Maltodextrine + proteins

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Lipid 2

Meal intake

Group Type ACTIVE_COMPARATOR

meal intake

Intervention Type DIETARY_SUPPLEMENT

Intake of meals characterized by lipid composition

Lipid 3

Meal intake

Group Type ACTIVE_COMPARATOR

meal intake

Intervention Type DIETARY_SUPPLEMENT

Intake of meals characterized by lipid composition

Lipid 4

meal intake

Group Type ACTIVE_COMPARATOR

meal intake

Intervention Type DIETARY_SUPPLEMENT

Intake of meals characterized by lipid composition

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

meal intake

Intake of meals characterized by lipid composition

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI : 19 - 24.9 kg.m-2
* Normal fasting glycemia
* Having obtained his informed consent.

Exclusion Criteria

* Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis.
* Have had a gastrointestinal surgery (with the exception of appendices resection).
* Malabsorption disorders
* Lactose intolerance
* Significant weight loss during the past three months (more than 5% of initial weight)
* Have a regular consumption of medication
* Regular supplements (vitamins and minerals) intake during the previous month
* Have an alcohol intake: \> 2 units a day
* Smoker (more than 2 cigarettes a day)
* Illicit substances intake, as stated on the medical screening questionnaire
* Allergy to any food or medication
* Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges
* Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
* Intense physical activity \> 3 hours per week
* Currently participating or having participated in another clinical trial during the past month.
* Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake
Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maurice Beaumont, MD

Role: PRINCIPAL_INVESTIGATOR

Nestlé / CDU / Metabolic Unit

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nestlé CDU / Metabolic Unit

Lausanne, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12.10.MET

Identifier Type: -

Identifier Source: org_study_id